Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP)
Snavely, Anna C. , Lee, Ju-Whei, Pugh, Stephanie L. , Arnold, Kathryn B. , Smith, Sydney A. , Tan, Angelina D, Dockter, Travis , Zahrieh, David M. , Gunn, Heather J., Gunn, Heather , Barlow, William E. , Culakova, Eva , Kittel, Carol , Hanlon, Bret M. , Tan, Angelina D, Dressler, Emily V.

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 65-72

10.1093/jncimonographs/lgae048 | PMID 39989039 Get It

Abstract The intracluster correlation coefficient (ICC) measures the correlation of observations within clusters and is a key parameter for power and sample size calculations for cluster randomized trials (CRTs). To facilitate the design of future CRTs within the National Cancer Institute Community Oncology Research Program (NCORP), all studies from the NCORP website were reviewed to identify completed CRTs. ICCs for primary and secondary outcomes (when available) were ascertained from these trials and summarized in this article as a resource for future trial development. Although ICCs are relatively small for many outcome cluster combinations, that is not always the case, so consideration should always be given to the specific outcome of interest, trial design, and type of cluster when estimating an ICC to facilitate trial development.
Practical design considerations for cluster randomized controlled trials: lessons learned in community oncology research
Dressler, Emily V. , Pugh, Stephanie L. , Zahrieh, David M. , Gunn, Heather J., Dressler, Emily V , Gunn, Heather , Unger, Joseph M. , Snavely, Anna C.

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 56-64

10.1093/jncimonographs/lgae053 | PMID 39989035 Get It

Abstract Cancer care delivery research trials conducted within the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) routinely implement interventions at the practice or provider level, necessitating the use of cluster randomized controlled trials (cRCTs). The intervention delivery requires cluster-level randomization instead of participant-level, affecting sample size calculation and statistical analyses to incorporate correlation between participants within a practice. Practical challenges exist in the conduct of these cRCTs due to unique trial network infrastructures, including the possibility of unequal participant accrual totals and rates and staggered study initiation by clusters, potentially with differences between randomized arms. Execution of cRCT designs can be complex, ie, if some clusters do not accrue participants, unintended cluster-level crossover occurs, how best to identify appropriate cluster-level stratification, timing of randomization, and multilevel eligibility criteria considerations. This article shares lessons learned with potential mitigation strategies from 3 NCORP cRCTs.
FOP: From Biomolecules to Hope
Kaplan, Frederick S. , Pignolo, Robert J. , Kaplan, Frederick S

Biomolecules | February 24, 2025 | Volume: 15 | Issue: 3 | Pages: 328

10.3390/biom15030328 | PMID 40149864 Get It

In the introduction to his 1970 textbook BIOCHEMISTRY, Albert Lehninger wrote “Living things are composed of lifeless molecules [...]
Body mass index changes after fecal microbiota transplantation for recurrent Clostridioides difficile infection
Sehgal, Kanika , Berry, Parul , Cho, Janice , Saffouri, George, Dierkhising, Ross , Battaglioli, Eric , Kashyap, Purna , Pardi, Darrell S. , Khanna, Sahil , Pardi, Darrell

Therapeutic Advances in Gastroenterology | February 24, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251321121 | PMID 39996135 Get It

Background: Fecal microbiota transplantation (FMT) is a successful therapy for Clostridioides difficile infection (CDI). FMT from overweight donors is speculated to influence the recipient’s body mass index (BMI) after administration for CDI. Objectives: We investigated changes in the recipient’s BMI after FMT in relation to the donor’s BMI. Design: We conducted a retrospective cohort study involving patients who underwent FMT for recurrent CDI at Mayo Clinic between 2012 and 2019. Methods: We analyzed demographic and donor data for patients undergoing FMT at Mayo Clinic (2012–2019). Recipient BMI (pre- and post-FMT) and donor BMI were extracted from medical records. Mixed-effects linear regression was used to evaluate the impact of donor BMI, donor BMI category, recipient baseline BMI, time before and after FMT, and interactions between these variables on overall BMI change and BMI change per month. Kaplan–Meier curves were used to assess BMI changes (⩾5 units) based on the last recorded post-FMT BMI. Results: We analyzed data from 401 patients with recorded BMI measurements before and after FMT. The median age of the recipients at the time of FMT was 59.1 years (interquartile range (IQR): 40.5–70.1 years), with 61.6% being female. The median BMI for recipients prior to FMT was 26.7 kg/m² (IQR: 22.7–31.6 kg/m²), while the median BMI of the donors was 24.5 kg/m2 (IQR: 23.9–27.5 kg/m2). Stool from donors with a normal BMI was used for 58.2% of recipients, while 41.8% received stool from pre-obese donors. Donor BMI data were missing for 3.2% of recipients. Donor BMI was not significantly associated with changes in recipient BMI; for each 1-unit increase in donor BMI, a 0.01-unit monthly increase was observed (95% confidence interval: −0.0003, 0.02; p = 0.11). The log-rank test for BMI increases (⩾+5) and decreases (⩽−5) revealed no significant differences among the donor BMI groups (Chi-squared = 4.4, p = 0.1 for increases, Chi-squared = 2, p = 0.4 for decreases). Conclusion: The lack of impact of donor BMI on BMI changes post-FMT suggests that these changes are more dependent on the recipient’s metabolic profile. Prospective, controlled trials are required to analyze these results more comprehensively.
Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare
Allyse, Megan , Agam, Preya , Bombard, Yvonne , Feys, Roel , Horstmann, McKenna , Kokayi, Assata , Isasi, Rosario , Meagher, Karen M. , Michie, Marsha , Musunuru, Kiran , Ormond, Kelly E. , Yap, Jane Q. , Allyse, Megan A , Riggan, Kirsten A , Yap, Jane Q , Meagher, Karen M , Riggan, Kirsten A.

The American Journal of Bioethics | February 24, 2025 | Volume: 25 | Issue: 6 | Pages: 11-25

10.1080/15265161.2025.2457713 | PMID 39988785 Get It

Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy
Enriquez‐Sarano, Maurice , Schaff, Hartzell V. , Michelena, Héctor I. , Roos, Carolyn M, Hagler, Michael A , Zhang, Heyu , Casaclang‐Verzosa, Grace , Huang, Runqing, Bartoo, Anna, Joyner, Michael J. , Kremers, Walter K. , Araoz, Philip A. , Singh, Gurpreet , Cunningham, Kevin Y. , Sung, Jaeyun , Dunagan, Brandon, Ye, Zi , Enriquez-Sarano, Maurice , Schaff, Hartzell , Michelena, Hector I , Hagler, Michael A , Casaclang-Verzosa, Grace, Ranadive, Sushant , Joyner, Michael J , Sabbah, Michael S. , Nkomo, Vuyisile T , Araoz, Philip A , Singh, Gurpreet , Walters, Michael A , Hawkinson, Jon , Cunningham, Kevin Y , Sung, Jaeyun , Ye, Zi , Miller, Jordan D. , Kremers, Walter K , Zhang, Bin , Ranadive, Sushant M. , Pislaru, Sorin V. , Nkomo, Vuyisile T. , Walters, Michael A. , Dunagan, Brandon

Circulation | February 24, 2025 | Volume: 151 | Issue: 13 | Pages: 913-930

10.1161/circulationaha.123.066523 | PMID 39989354 Get It

BACKGROUND: Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS. METHODS: We used quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry to characterize sGC signaling and the biological effects of ataciguat on signaling cascades related to nitric oxide, calcification, and fibrosis in excised human aortic valve tissue, aortic valve interstitial cells, and mouse aortic valves. We then conducted randomized, placebo-controlled phase I (14-day safety/tolerance) and phase II (6-month efficacy) trials in patients with moderate aortic valve stenosis. RESULTS: In excised human tissue, we found robust losses in sGC signaling despite upregulation of sGC subunits. In vitro, ataciguat increased sGC signaling and reduced BMP2 (bone morphogenetic protein 2) signaling in aortic valve interstitial cells. In mice with established FCAVS, treatment with ataciguat attenuated BMP signaling and slowed progression of valve calcification and dysfunction. In a phase I, randomized, placebo-controlled trial, treatment with ataciguat for 2 weeks was safe and well tolerated in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02049203). In a separate phase II, randomized, placebo-controlled trial, treatment with ataciguat for 6 months slowed the progression of aortic valve calcification and tended to slow the progression of valvular and ventricular dysfunction in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02481258). CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02049203. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02481258.
Ditching the defaults: Assessing the impact of default duration removal on antibiotic prescriptions originating in the emergency department
Abel, A. L. , Stevens, Ryan W. , Ausman, Sara , Hannan, Kellie N. Arensman , Ilges, Dan , Kooda, Kirstin , Lessard, Sarah , Willis, Courtney , Jensen, Kelsey , Van Abel, Amy L , Arensman Hannan, Kellie , Willis, Courtney M , Jensen, Kelsey , Ausman, Sara E , Stevens, Ryan W , Ilges, Dan , Rivera, Christina G.

Infection Control & Hospital Epidemiology | February 24, 2025 | Volume: 46 | Issue: 5 | Pages: 548-550

10.1017/ice.2025.31 | PMID 39989314 Get It

Abstract Reducing antimicrobial exposure by limiting the duration of therapy is an effective antimicrobial stewardship strategy. In this article, we describe the impact of modification of the electronic health record to remove default durations of therapy on ambulatory antibiotic prescriptions issued from emergency departments in a large, multicenter health system.
From the Editor-in-Chief’s Desk: Psychedelic Therapeutics—Something Old and Something New
Croarkin, Paul E. , Croarkin, Paul E

Journal of Child and Adolescent Psychopharmacology | February 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/cap.2025.0017 | PMID 39989110 Get It

A spatial transcriptomics atlas of live donors reveals unique zonation patterns in the healthy human liver
Yakubovsky, Oran , Egozi, Adi, Halpern, Keren Bahar , Barkai, Tal, Harnik, Yotam , Novoselsky, Roy , Goliand, Inna , Keren‐Shaul, Hadas , Hirsch, Dana , Mayer, Chen , Pery, Ron, Pencovich, Niv , Taner, Timucin, Nachmany, Ido , Afriat, Amichay , Kohanim, Yael Korem , Golani, Ofra , Addadi, Yoseph , Kedmi, Merav , Fellus-Alyagor, Liat , Pery, Ron, Itzkovitz, Shalev

No container title available | February 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.22.639181 Get It

Abstract Reconstructing gene expression atlases for human tissues is challenging due to limited access to healthy samples from live donors. Neurologically deceased donors often show ischemic changes, while tissues near diseased regions may have altered gene expression. The liver, with its unique regenerative capacity, allows analysis from live healthy donors (LHDs). Using spatial transcriptomics (Visum, Visium HD and MERFISH), we analyzed 16 liver samples: eight from young LHDs and eight from patients with liver pathology, sampling ‘adjacent normal’ tissue. LHD livers displayed significant gene expression differences from ‘adjacent normal’ tissues. Hepatocytes exhibited marked zonation along the porto-central axis of liver lobules, with key functions pericentrally shifted compared to other mammals. Our atlas identified dynamic programs in early steatotic hepatocytes, showing transitions from lipid uptake in low-lipid regions to insulin hypersensitivity in high-lipid regions. This study presents a spatial gene expression reference for the healthy human liver and insights into hepatocyte adaptations in steatosis.
Abstract A061: Discovery of resilient T cells from patients in responses to combination immunotherapy and their metabolic features
Gicobi, Joanina K. , Dong, Haidong

Cancer Immunology Research | February 23, 2025 | Volume: 13 | Issue: 2_Supplement | Pages: A061-A061

10.1158/2326-6074.io2025-a061 Get It

Abstract Salvage combination therapy including radiotherapy and immunotherapy has been used to reduce tumor burden and tumor-related symptoms in patients with advanced cancer that is refractory to ICI monotherapy. Among those patients who experienced significant tumor regression in responses to combination therapy, we identified a rebound of effector CD8+ T cells with high cytotoxic capacity and metabolic fitness. We use the term T cell resilience to explain the rebound of cytotoxic CD8+ T cells in response to combination therapy and examine the underlying mechanisms of T cell resilience. Resilient T cells are enriched in CX3CR1+ CD8+ T cells with low mitochondrial membrane potential, accumulate less reactive oxygen species (ROS), and express more malic enzyme 1 (ME1). We found ME1 overexpression enhanced the cytotoxicity and expansion of effector CD8+ T cells partially via the type I interferon pathway. ME1 also increased mitochondrial respiration while maintaining the redox state balance. Importantly, ME1 increased the cytotoxicity of peripheral lymphocytes from patients with advanced cancers and improve the efficacy of tumor-infiltrating lymphocytes (TIL) therapy in animal models. Our results demonstrate the presence of resilient T cells in patients, suggest that T cell resiliency is attributed to their metabolic reprogram mediated by ME1, which is a new T cell-intrinsic therapeutic target for T cell-based immunotherapy. Citation Format: Haidong Dong, Joanina K Gicobi. Discovery of resilient T cells from patients in responses to combination immunotherapy and their metabolic features [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A061.